These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11194593)

  • 1. Rate dependence of the effect of antiarrhythmic drugs delaying cardiac repolarization: an overview.
    Dorian P; Newman D
    Europace; 2000 Oct; 2(4):277-85. PubMed ID: 11194593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New aspects of the electrophysiologic effect of antiarrhythmic agents].
    Antoni H; Weirich J
    Herz; 1990 Apr; 15(2):61-9. PubMed ID: 2188893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remodelling of cardiac repolarization: how homeostatic responses can lead to arrhythmogenesis.
    Michael G; Xiao L; Qi XY; Dobrev D; Nattel S
    Cardiovasc Res; 2009 Feb; 81(3):491-9. PubMed ID: 18826964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
    Calderone V; Cavero I
    Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current classification of anti-arrhythmia agents].
    Weirich J; Wenzel W
    Z Kardiol; 2000; 89 Suppl 3():62-7. PubMed ID: 10810787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mechanisms of action of class III anti-arrhythmia agents].
    Adamantidis MM
    Arch Mal Coeur Vaiss; 1995 Jan; 88 Spec No 1():33-40. PubMed ID: 7786143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of cardiac potassium channels.
    Tamargo J; Caballero R; Gómez R; Valenzuela C; Delpón E
    Cardiovasc Res; 2004 Apr; 62(1):9-33. PubMed ID: 15023549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis of cardiac action potential repolarization.
    Rudy Y
    Ann N Y Acad Sci; 2008 Mar; 1123():113-8. PubMed ID: 18375583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ischemic modulation of vulnerable period and the effects of pharmacological treatment of ischemia-induced arrhythmias: a simulation study.
    Cimponeriu A; Starmer CF; Bezerianos A
    IEEE Trans Biomed Eng; 2003 Feb; 50(2):168-77. PubMed ID: 12665030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two components of delayed rectifier K+ current in heart: molecular basis, functional diversity, and contribution to repolarization.
    Cheng JH; Kodama I
    Acta Pharmacol Sin; 2004 Feb; 25(2):137-45. PubMed ID: 14769199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New class III antiarrhythmic drugs.
    Katritsis D; Camm AJ
    Eur Heart J; 1993 Nov; 14 Suppl H():93-9. PubMed ID: 8293759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle.
    Jost N; Virág L; Bitay M; Takács J; Lengyel C; Biliczki P; Nagy Z; Bogáts G; Lathrop DA; Papp JG; Varró A
    Circulation; 2005 Sep; 112(10):1392-9. PubMed ID: 16129791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers.
    Fedida D; Orth PM; Hesketh JC; Ezrin AM
    J Cardiovasc Electrophysiol; 2006 May; 17 Suppl 1():S71-S78. PubMed ID: 16686685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular electrophysiological effect of terikalant in the dog heart.
    Biliczki P; Acsai K; Virág L; Tálosi L; Jost N; Biliczki A; Papp JG; Varró A
    Eur J Pharmacol; 2005 Mar; 510(3):161-6. PubMed ID: 15763239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The canine virtual ventricular wall: a platform for dissecting pharmacological effects on propagation and arrhythmogenesis.
    Benson AP; Aslanidi OV; Zhang H; Holden AV
    Prog Biophys Mol Biol; 2008; 96(1-3):187-208. PubMed ID: 17915298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of action of class III agents and their clinical relevance.
    Dorian P
    Europace; 2000 Jul; 1 Suppl C():C6-9. PubMed ID: 11220521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.
    Riera AR; Uchida AH; Ferreira C; Ferreira Filho C; Schapachnik E; Dubner S; Zhang L; Moffa PJ
    Cardiol J; 2008; 15(3):209-19. PubMed ID: 18651412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New anti-arrhythmics--hope or disappointment?].
    Touboul P
    Arch Mal Coeur Vaiss; 2004 Nov; 97(11):1048-53. PubMed ID: 15609905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Principles for the classification of anti-arrhythmia agents in cardiac arrhythmias].
    Ravens U
    Z Kardiol; 1992; 81 Suppl 4():119-25. PubMed ID: 1290288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.